ArticleJournal of veterinary internal medicine2018
Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.
Article in Journal of veterinary internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Oral chemotherapy agents in cats: clinical uses, administration and side effects.Journal of feline medicine and surgery · 2026Review
- Case Report: Modified pulse-dose melphalan therapy for canine colorectal extramedullary plasmacytoma with suspected hepatic dissemination following surgical excision.Frontiers in veterinary science · 2026Article
- Refractory Multiple Myeloma in a West Highland White Terrier: Clinical Presentations and Therapeutic Interventions.Animals : an open access journal from MDPI · 2025Article
- Thalidomide as a rescue protocol for treatment of multiple myeloma in dogs: preliminary data from a multicentre retrospective study.Frontiers in veterinary science · 2025Article
- Extramedullary plasmacytoma of the oral cavity metastasising to both kidneys in a dog.Veterinary medicine and science · 2023Article
- Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma.Veterinary and comparative oncology · 2023Article
- Computed tomographic findings in dogs with multiple myeloma.Veterinary medicine and science · 2023Article
- A feline case of multiple myeloma treated with bortezomib.BMC veterinary research · 2022Article
- Multiple myeloma involving the gastrointestinal tract in an English Springer Spaniel.Veterinary medicine and science · 2022Article
- Comparative Oncology Assessment of a Novel Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs.Molecular cancer therapeutics · 2022Article
- Bite-size introduction to canine hematologic malignancies.Blood advances · 2022Review
- Blood neutrophil-to-lymphocyte ratio (NLR) as a diagnostic marker in dogs with chronic enteropathy.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2021Article
- Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma.Journal of veterinary internal medicine · 2021Article
- Determination of a serum total calcium concentration threshold for accurate prediction of ionized hypercalcemia in dogs with and without hyperphosphatemia.Journal of veterinary internal medicine · 2020Article
- Plasma cell leukemia with plasmablastic morphology in a dog.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2019Article
- Clinicopathological findings in 41 dogs (2008-2018) naturally infected with Ehrlichia ewingii.Journal of veterinary internal medicine · 2019Article
- Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.Journal of veterinary internal medicine · 2018Article
- Descriptive analysis and prognostic factors in cats with myeloma-related disorders: A multicenter retrospective study of 50 cases.Journal of veterinary internal medicineArticle
- Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols.Open veterinary journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple myeloma (MM) in dogs typically is treated with melphalan. A daily melphalan dosing schedule reportedly is well tolerated and associated with favorable outcome. Although anecdotally a pulse dose regimen has resulted in successful responses, little long-term outcome and safety data is available regarding this dosing regimen for dogs with MM. HYPOTHESIS/
objectives(1) To compare outcome and adverse event profiles between pulse dose and daily dose melphalan schedules and (2) to report prognostic factors in dogs with MM treated with melphalan. We hypothesized that both protocols would have similar outcomes and tolerability. ANIMALS: Thirty-eight client-owned dogs diagnosed with MM receiving pulse dose (n = 17) or daily dose (n = 21) melphalan.
methodsRetrospective cohort study assessing outcome and adverse events in dogs receiving either protocol. Risk factors were evaluated for their prognostic relevance.
resultsBoth regimens were well tolerated and similarly effective, with an overall median survival time of 930 days. Renal disease and neutrophil-to-lymphocyte ratio (NLR) were negative prognostic factors, whereas hypercalcemia and osteolytic lesions were not prognostic factors in this study population. CONCLUSIONS AND CLINICAL IMPORTANCE: Positive results support the use of either dosing regimen for the treatment of dogs with MM, and renal disease and NLR were negative prognostic factors. Prospective, controlled, and randomized studies are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.